Prof. Dr. Mutlu Arat
Timeline
Scientific work
-
2019The Lancet«Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study»
-
2021The Lancet«Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial»
-
2020The Lancet Haematology«Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation»
-
2016Bone Marrow Transplantation«Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation»
-
2011Nature Genetics«NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules»
Where they practise
Direct contract with BergemHealth at every listed clinic.
Tell me about your case — I’ll read it personally.
Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.
Open the consultation form- Reply within 4 hours during business hours
- Confidentiality guaranteed
- Coordinator-translator inside the doctor’s office
- Tumour board of 2–3 professors within 72 hours
Similar BergemHealth professors
Adjacent specialties and second opinions. Direct contracts, verified cases.